Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030.
Epidemiological survey
Hepatitis viruses
Islands
Japan
Ship-based survey
Journal
Euroasian journal of hepato-gastroenterology
ISSN: 2231-5047
Titre abrégé: Euroasian J Hepatogastroenterol
Pays: India
ID NLM: 101577625
Informations de publication
Date de publication:
Historique:
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
ppublish
Résumé
In 1990, an epidemiological survey by ship in some Japanese islands revealed high prevalence of hepatitis viruses and human T cell leukemia virus (HTLV). A second prevalence study of these viruses were accomplished in 2018, 28 years after initial survey. Analysis of these studies provide insights about strategies of elimination of hepatitis viruses at remote areas. In 2018, prevalence of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and HTLV was checked in 305 subjects in the islands those covered in 1990's survey. Hepatitis A virus was checked by the presence of anti-HAV IgG in sera; HBV was affirmed when hepatitis B surface antigen (HBsAg) in sera. Hepatitis C virus infection was evaluated by the presence of antibody to HCV (anti-HCV) and infection with HTLV was estimated by immunoassay. The methodology of assessment of different hepatitis viruses were optimized on the basis of present scientific knowhow. In 1990, the prevalence of HAV (presence of anti-HAV), HBV (presence of HBsAg), HCV (positivity for anti-HCV), and HTLV was found in 79.3%, 11.1%, 2.2%, and 3.3% of apparently health subjects of the islands, respectively. The prevalence of HAV, HBV, HCV, and HTLV was 47.9%, 4.6%, 1.0%, and 3.0%, respectively, in 2018. A shift of age of infected persons tilted towards right as the days progressed. The study indicates a scenario of elimination of hepatitis viruses in Japan as lower trends of prevalence of HAV, HBV, and HCV have been recorded in 2018 compared with 1990, mainly by preventive measures. The most notable finding is that there are almost no new case below the age of 40 years, indicating an effective containment measure against these viruses. Akao T, Onji M, Kawasaki K,
Identifiants
pubmed: 32117691
doi: 10.5005/jp-journals-10018-1304
pmc: PMC7047309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57-62Informations de copyright
Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
J Gastroenterol Hepatol. 1991 Nov-Dec;6(6):599-602
pubmed: 1685926
J Infect Dis. 2018 Apr 11;217(9):1383-1389
pubmed: 29346571
Vaccine. 2015 Nov 9;33(45):6029-36
pubmed: 25957664
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):477-487
pubmed: 30982721
Intervirology. 2011;54(4):185-95
pubmed: 21454956
Lancet Infect Dis. 2002 Jul;2(7):395-403
pubmed: 12127351
J Biomed Sci. 2015 Oct 20;22:92
pubmed: 26487087
J Infect Dis. 2000 Jul;182(1):12-7
pubmed: 10882576
World J Gastroenterol. 2018 Nov 28;24(44):4959-4961
pubmed: 30510370
J Med Virol. 2012 Feb;84(2):327-35
pubmed: 22170555